Gilead Sciences buys Arcellx in $7.8 billion deal. With this, it acquires its partner in the development of CAR-T therapy anito-cel against multiple myeloma. Anito-cel is the first BCMA CAR-T drug using the new D-Domain binder from Arcellx. Kite (a Gilead subsidiary) and Arcellx have entered into a global collaboration to jointly develop and commercialize anito-cel for patients with relapsed or refractory multiple myeloma. Anito-cel is currently in a pivotal phase 2 clinical trial. In a study of 117 patients, 96% of patients responded to treatment, with 74% achieving complete remission. No major security issues have been reported. Kite and Arcellx will jointly develop and commercialize the drug in the US, Kite outside the US.